3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
137
Parkinson Disease 4, Autosomal Dominant Lewy Body
125
Melanoma
95
Neoplasms
75
Squamous Cell Carcinoma of Head and Neck
65
Colorectal Neoplasms
42
Triple Negative Breast Neoplasms
38
Carcinoma, Renal Cell
37
Lung Neoplasms
36
Stomach Neoplasms
35
Head and Neck Neoplasms
34
Breast Neoplasms
34
Urinary Bladder Neoplasms
32
Neoplasm Metastasis
32
Carcinoma, Hepatocellular
32
Pancreatic Neoplasms
30
Ovarian Neoplasms
29
Carcinoma, Transitional Cell
25
Endometrial Neoplasms
19
Recurrence
16
Sarcoma
15
Esophageal Neoplasms
15
Carcinoma
15
Uterine Cervical Neoplasms
14
Prostatic Neoplasms
14
Small Cell Lung Carcinoma
13
Lymphoma
13
Fallopian Tube Neoplasms
13
Carcinoma, Squamous Cell
13
Lymphoma, Non-Hodgkin
12
Interventions
pembrolizumab
2
Platinum
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Solid Neoplasms
×
pembrolizumab
×
Clear all
NCT04420884
2026-04-08
iintune-1
Takeda
Phase 1/2
Completed
248 enrolled
NCT03364049
2021-11-15
MK-7162-002
Merck Sharp & Dohme LLC
Phase 1
Completed
33 enrolled
19 charts